Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aPD1-MSLN-CAR T cells
- Development stage
- Unknown
- Lead developer
- Shanghai Cell Therapy Group
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
aPD1-MSLN-CAR T cells are an investigational autologous chimeric antigen receptor (CAR) T cell therapy engineered to target mesothelin (MSLN), an antigen overexpressed in various solid tumors. These CAR T cells are further modified to express or secrete an anti-PD-1 nanobody or antibody, which blocks the programmed cell death protein 1 (PD-1) pathway on immune and tumor cells. This dual mechanism aims to enhance antitumor activity by both directly targeting MSLN-positive cancer cells and overcoming local immunosuppression mediated by the PD-1/PD-L1 axis. The therapy is being evaluated for safety and efficacy in patients with advanced solid tumors expressing mesothelin[2][3][4][6].
- Other names
- non-viral aPD1-MSLN JL-Lightning–CAR-Tautologous PD-1 nanobody-expressing anti-mesothelin CAR T cells
02
Targets
MesothelinPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on aPD1-MSLN-CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aPD1-MSLN-CAR T cells.